達剛控股(300103.SZ)與華昱集團簽訂戰略合作框架協議 擬開展道路智慧運維養護託管合作項目
格隆匯 8 月 5日丨達剛控股(300103.SZ)公佈,公司與深圳華昱投資開發(集團)有限公司(“華昱集團”)於2020年8月5日簽訂了《戰略合作框架協議》,雙方擬在華昱集團所在地開展道路智慧運維養護託管合作項目。
此次《戰略合作框架協議》的簽訂,符合公司整體戰略發展規劃,預示着公司城市道路智慧運維管理戰略規劃的持續落地,可進一步提升公司綜合競爭實力,助力產業升級。
此次簽訂的《戰略合作框架協議》未涉及具體金額,對公司當年及未來經營業績和經營利潤的影響存在一定的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.